000893930 001__ 893930
000893930 005__ 20220930130321.0
000893930 0247_ $$2doi$$a10.3389/fcvm.2021.704657
000893930 0247_ $$2Handle$$a2128/28107
000893930 0247_ $$2altmetric$$aaltmetric:108899656
000893930 0247_ $$2pmid$$a34307509
000893930 0247_ $$2WOS$$aWOS:000674908500001
000893930 037__ $$aFZJ-2021-02940
000893930 082__ $$a610
000893930 1001_ $$0P:(DE-HGF)0$$aPickel, Simone$$b0
000893930 245__ $$aThe β$_{2}$-Subunit of Voltage-Gated Calcium Channels Regulates Cardiomyocyte Hypertrophy
000893930 260__ $$aLausanne$$bFrontiers Media$$c2021
000893930 3367_ $$2DRIVER$$aarticle
000893930 3367_ $$2DataCite$$aOutput Types/Journal article
000893930 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1625989138_31107
000893930 3367_ $$2BibTeX$$aARTICLE
000893930 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000893930 3367_ $$00$$2EndNote$$aJournal Article
000893930 520__ $$aL-type voltage-gated calcium channels (LTCCs) regulate crucial physiological processes in the heart. They are composed of the Cavα1 pore-forming subunit and the accessory subunits Cavβ, Cavα2δ, and Cavγ. Cavβ is a cytosolic protein that regulates channel trafficking and activity, but it also exerts other LTCC-independent functions. Cardiac hypertrophy, a relevant risk factor for the development of congestive heart failure, depends on the activation of calcium-dependent pro-hypertrophic signaling cascades. Here, by using shRNA-mediated Cavβ silencing, we demonstrate that Cavβ2 downregulation enhances α1-adrenergic receptor agonist-induced cardiomyocyte hypertrophy. We report that a pool of Cavβ2 is targeted to the nucleus in cardiomyocytes and that the expression of this nuclear fraction decreases during in vitro and in vivo induction of cardiac hypertrophy. Moreover, the overexpression of nucleus-targeted Cavβ2 in cardiomyocytes inhibits in vitro-induced hypertrophy. Quantitative proteomic analyses showed that Cavβ2 knockdown leads to changes in the expression of diverse myocyte proteins, including reduction of calpastatin, an endogenous inhibitor of the calcium-dependent protease calpain. Accordingly, Cavβ2-downregulated cardiomyocytes had a 2-fold increase in calpain activity as compared to control cells. Furthermore, inhibition of calpain activity in Cavβ2-downregulated cells abolished the enhanced α1-adrenergic receptor agonist-induced hypertrophy observed in these cells. Our findings indicate that in cardiomyocytes, a nuclear pool of Cavβ2 participates in cellular functions that are independent of LTCC activity. They also indicate that a downregulation of nuclear Cavβ2 during cardiomyocyte hypertrophy promotes the activation of calpain-dependent hypertrophic pathways.
000893930 536__ $$0G:(DE-HGF)POF4-5243$$a5243 - Information Processing in Distributed Systems (POF4-524)$$cPOF4-524$$fPOF IV$$x0
000893930 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000893930 7001_ $$0P:(DE-HGF)0$$aCruz-Garcia, Yiliam$$b1
000893930 7001_ $$0P:(DE-HGF)0$$aBandleon, Sandra$$b2
000893930 7001_ $$0P:(DE-HGF)0$$aBarkovits, Katalin$$b3
000893930 7001_ $$0P:(DE-HGF)0$$aHeindl, Cornelia$$b4
000893930 7001_ $$0P:(DE-HGF)0$$aVölker, Katharina$$b5
000893930 7001_ $$0P:(DE-HGF)0$$aAbeßer, Marco$$b6
000893930 7001_ $$0P:(DE-HGF)0$$aPfeiffer, Kathy$$b7
000893930 7001_ $$0P:(DE-HGF)0$$aSchaaf, Alice$$b8
000893930 7001_ $$0P:(DE-HGF)0$$aMarcus, Katrin$$b9
000893930 7001_ $$0P:(DE-HGF)0$$aEder-Negrin, Petra$$b10
000893930 7001_ $$0P:(DE-HGF)0$$aKuhn, Michaela$$b11
000893930 7001_ $$0P:(DE-Juel1)180990$$aMiranda Laferte, Erick$$b12$$eCorresponding author$$ufzj
000893930 773__ $$0PERI:(DE-600)2781496-8$$a10.3389/fcvm.2021.704657$$gVol. 8, p. 704657$$p704657$$tFrontiers in Cardiovascular Medicine$$v8$$x2297-055X$$y2021
000893930 8564_ $$uhttps://juser.fz-juelich.de/record/893930/files/fcvm-08-704657.pdf$$yOpenAccess
000893930 8767_ $$d2021-07-08$$eAPC$$jDeposit$$lDeposit: Frontiers$$zUSD 2116.50
000893930 909CO $$ooai:juser.fz-juelich.de:893930$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000893930 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180990$$aForschungszentrum Jülich$$b12$$kFZJ
000893930 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5243$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x0
000893930 9141_ $$y2021
000893930 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-27
000893930 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000893930 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000893930 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000893930 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT CARDIOVASC MED : 2019$$d2021-01-27
000893930 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-01-27
000893930 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-01-27
000893930 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-27
000893930 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-27
000893930 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-27
000893930 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-27
000893930 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000893930 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-01-27
000893930 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-27
000893930 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-27
000893930 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-27
000893930 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-27
000893930 920__ $$lyes
000893930 9201_ $$0I:(DE-Juel1)IBI-1-20200312$$kIBI-1$$lMolekular- und Zellphysiologie$$x0
000893930 980__ $$ajournal
000893930 980__ $$aVDB
000893930 980__ $$aUNRESTRICTED
000893930 980__ $$aI:(DE-Juel1)IBI-1-20200312
000893930 980__ $$aAPC
000893930 9801_ $$aAPC
000893930 9801_ $$aFullTexts